BioCentury
ARTICLE | Clinical News

Cytokinetics starts Phase II trial of CK-2127107 to treat ALS

September 29, 2017 9:26 PM UTC

Cytokinetics Inc. (NASDAQ:CYTK) began the Phase II FORTITUDE-ALS trial of CK-2127107 (CK-107) to treat amyotrophic lateral sclerosis (ALS). The double-blind, placebo-controlled trial will enroll about 450 patients to receive 150, 300, or 450 mg oral CK-2127107 twice daily for 12 weeks.

The trial’s primary endpoint is change from baseline to 12 weeks in percent predicted slow vital capacity (SVC). Secondary endpoints include slope of the change from baseline in the mega-score of muscle strength measured by hand held dynamometry and hand grip dynamometry, change from baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) score, safety and pharmacokinetics...

BCIQ Target Profiles

Sarcomere